Merck (NYSE: MRK) reported Q3 EPS of $0.90, $0.02 better than the analyst estimate of $0.88. Revenue for the quarter came in at $10.56 billion versus the consensus estimate of $10.66 billion.

“Last October, we launched a multi-year initiative to transform Merck and build a platform for sustained, future growth,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “One year later, we delivered solid third-quarter results and are making steady progress in our transformation, including divesting non-core assets, reducing our expense base and investing in our promising new product launches and pipeline.”

Select Revenue Highlights

Worldwide sales were $10.6 billion for the third quarter of 2014, a decrease of 4 percent compared with the third quarter of 2013, including a 1 percent positive impact from foreign exchange. The decline includes $425 million of lower sales due to divestitures and the termination of the joint venture with AstraZeneca (AZ).

The following table reflects sales of the company’s top pharmaceutical products, as well as total sales of Animal Health and Consumer Care products.

Merck sees FY2014 EPS of $3.46-$3.50, versus the consensus of $3.47.

For earnings history and earnings-related data on Merck (MRK) click here.